Literature DB >> 26372817

Validation of the Besta Neurological Institute rating scale for myasthenia gravis.

Carlo Antozzi1, Greta Brenna1, Fulvio Baggi1, Giorgia Camera1, Lorenzo Maggi1, Cristiana Rezzani2, Cristina Montomoli2, Renato Mantegazza1.   

Abstract

INTRODUCTION: We validated the scale for myasthenia gravis (MG) developed at the Neurological Institute Foundation of Milan (INCB-MG scale).
METHODS: A total of 174 patients were evaluated with the INCB-MG and compared with the MG Composite (MGC) as the gold standard. Dimensionality, reliability, and validity of the INCB-MG scale were studied by principal component factor analysis, Cronbach alpha, and Pearson correlation coefficients; interobserver reliability was calculated by the weighted Cohen K coefficient.
RESULTS: Generalized and bulbar INCB-MG subscales were unidimensional with excellent consistency; the INCB-MG and MGC scales were strongly correlated. Fatigability assessment was correlated with the INCB-MG generalized, bulbar, and respiratory subscales.
CONCLUSIONS: The INCB-MG scale is a reliable tool to assess MG and is strongly correlated with the MGC. The INCB-MG scale is a valid tool for every day practice and should be further investigated for its application in clinical trials.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  Myasthenia Gravis; disability; outcome; rating scale; validation

Mesh:

Year:  2015        PMID: 26372817     DOI: 10.1002/mus.24911

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  4 in total

1.  Validity, reliability, and sensitivity to change of the myasthenia gravis activities of daily living profile in a sample of Italian myasthenic patients.

Authors:  Alberto Raggi; Carlo Antozzi; Fulvio Baggi; Matilde Leonardi; Lorenzo Maggi; Renato Mantegazza
Journal:  Neurol Sci       Date:  2017-08-05       Impact factor: 3.307

2.  Validation of the MG-DIS: a disability assessment for myasthenia gravis.

Authors:  Alberto Raggi; Matilde Leonardi; Silvia Schiavolin; Carlo Antozzi; Greta Brenna; Lorenzo Maggi; Renato Mantegazza
Journal:  J Neurol       Date:  2016-03-01       Impact factor: 4.849

3.  Amifampridine phosphate in the treatment of muscle-specific kinase myasthenia gravis: a phase IIb, randomized, double-blind, placebo-controlled, double crossover study.

Authors:  Silvia Bonanno; Maria Barbara Pasanisi; Rita Frangiamore; Lorenzo Maggi; Carlo Antozzi; Francesca Andreetta; Angela Campanella; Greta Brenna; Lorenzo Cottini; Renato Mantegazza
Journal:  SAGE Open Med       Date:  2018-12-17

4.  Validation of the Italian version of the Myasthenia Gravis Impairment Index (MGII).

Authors:  Francesca Pasqualin; Carolina Barnett; Silvia Vittoria Guidoni; Elisa Albertini; Mario Ermani; Domenico Marco Bonifati
Journal:  Neurol Sci       Date:  2021-09-09       Impact factor: 3.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.